Wang Shulin, Li Yunpeng, Song Xudong, Wang Xianbao, Zhao Cong, Chen Aihua, Yang Pingzhen
Department of Cardiology, Zhujiang Hospital of Southern Medical University, No. 253, Gongye Road, Guangzhou, 510280, China.
J Transl Med. 2015 Jul 2;13:209. doi: 10.1186/s12967-015-0578-x.
Febuxostat is a selective inhibitor of xanthine oxidase (XO). XO is a critical source of reactive oxygen species (ROS) during myocardial ischemia/reperfusion (I/R) injury. Inhibition of XO is therapeutically effective in I/R injury. Evidence suggests that febuxostat exerts antioxidant effects by directly scavenging ROS. The present study was performed to investigate the effects of febuxostat on myocardial I/R injury and its underlying mechanisms.
We utilized an in vivo mouse model of myocardial I/R injury and an in vitro neonatal rat cardiomyocyte (NRC) model of hypoxia/reoxygenation (H/R) injury. Mice were randomized into five groups: Sham, I/R (I/R + Vehicle), I/R + FEB (I/R + febuxostat), AL + I/R (I/R + allopurinol) and FEB (febuxostat), respectively. The I/R + FEB mice were pretreated with febuxostat (5 mg/kg; i.p.) 24 and 1 h prior to I/R. NRCs received febuxostat (1 and 10 µM) at 24 and 1 h before exposure to hypoxia for 3 h followed by reoxygenation for 3 h. Cardiac function, myocardial infarct size, serum levels of creatine kinase (CK) and lactate dehydrogenase (LDH), and myocardial apoptotic index (AI) were measured in order to ascertain the effects of febuxostat on myocardial I/R injury. Hypoxia/reperfusion (H/R) injury in NRCs was examined using MTT, LDH leakage assay and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. The underlying mechanisms were determined by measuring ROS production, mitochondrial membrane potential (ΔΨm), and expression of cytochrome c, cleaved caspases as well as Bcl-2 protein levels.
Myocardial I/R led to an elevation in the myocardial infarct size, serum levels of CK and LDH, cell death and AI. Furthermore, I/R reduced cardiac function. These changes were significantly attenuated by pretreatment with febuxostat and allopurinol, especially by febuxostat. Febuxostat also protected the mitochondrial structure following myocardial I/R, inhibited H/R-induced ROS generation, stabilized the ΔΨm, alleviated cytosolic translocation of mitochondrial cytochrome C, inhibited activation of caspase-3 and -9, upregulated antiapoptotic proteins and downregulated proapoptotic proteins.
This study revealed that febuxostat pretreatment mediates the cardioprotective effects against I/R and H/R injury by inhibiting mitochondrial-dependent apoptosis.
非布司他是一种黄嘌呤氧化酶(XO)的选择性抑制剂。XO是心肌缺血/再灌注(I/R)损伤过程中活性氧(ROS)的关键来源。抑制XO对I/R损伤具有治疗效果。有证据表明,非布司他通过直接清除ROS发挥抗氧化作用。本研究旨在探讨非布司他对心肌I/R损伤的影响及其潜在机制。
我们使用了心肌I/R损伤的体内小鼠模型和缺氧/复氧(H/R)损伤的体外新生大鼠心肌细胞(NRC)模型。将小鼠随机分为五组:假手术组、I/R组(I/R + 溶剂)、I/R + FEB组(I/R + 非布司他)、AL + I/R组(I/R + 别嘌醇)和FEB组(非布司他)。I/R + FEB组小鼠在I/R前24小时和1小时腹腔注射非布司他(5 mg/kg)。NRC在缺氧3小时前24小时和1小时接受非布司他(1和10 μM)处理,随后复氧3小时。测量心脏功能、心肌梗死面积、血清肌酸激酶(CK)和乳酸脱氢酶(LDH)水平以及心肌凋亡指数(AI),以确定非布司他对心肌I/R损伤的影响。使用MTT、LDH泄漏试验和末端脱氧核苷酸转移酶dUTP缺口末端标记(TUNEL)试验检测NRC中的缺氧/复氧(H/R)损伤。通过测量ROS产生、线粒体膜电位(ΔΨm)以及细胞色素c、裂解的半胱天冬酶的表达以及Bcl-2蛋白水平来确定潜在机制。
心肌I/R导致心肌梗死面积、血清CK和LDH水平升高、细胞死亡和AI增加。此外,I/R降低了心脏功能。非布司他和别嘌醇预处理可显著减轻这些变化,尤其是非布司他。非布司他还可保护心肌I/R后的线粒体结构,抑制H/R诱导的ROS生成,稳定ΔΨm,减轻线粒体细胞色素C的胞质转位,抑制半胱天冬酶-3和-9的激活,上调抗凋亡蛋白并下调促凋亡蛋白。
本研究表明,非布司他预处理通过抑制线粒体依赖性凋亡介导对I/R和H/R损伤的心脏保护作用。